Roche acquires Loxo, Bayer in a genetically defined cancer class

Roche acquires Loxo, Bayer in a genetically defined cancer class https://www.eresviral.com/wp-content/uploads/2018/10/Roche-adquiere-a-Loxo-Bayer-en-una-clase-de-cáncer-definida-genéticamente

Roche acquires Loxo, Bayer in a genetically defined cancer class







MUNICH (Reuters) - Roche's entrectinib cancer pill was shown to shrink tumors in 57 percent of patients within a group that can only be identified by genetic profile, as the Swiss pharmaceutical company challenges an alliance of Bayer and Loxo Oncology in a new area of ​​targeted treatment.  











PHOTO OF ARCHIVE: The logo of the Swiss pharmaceutical company Roche can be seen at its headquarters in Basel, Switzerland, on February 1, 2018. REUTERS / Arnd Wiegmann / File Photo





The results of the trial in patients with a genetic abnormality known as NTRK fusion, which occurs in less than 1 percent in a variety of tumor types, were presented at the annual congress of the European Society of Medical Oncology (ESMO) in Munich on Sunday. 

Bayer, of Germany, and US partner Loxo, in turn, published data on their rival larotrectinib compound, which improved slightly on previous high-efficiency readings in an extended trial. 

Traditionally, oncologists have made treatment decisions based on where a tumor began in the body, increasingly helped by the growing knowledge of the complex genetic factors of cancer. 

Under the agnostic tumor approach, also known as pan-tumor, drug manufacturers omit the perspective of the organ of origin and regroup patients based only on characteristic gene mutations, but success in real life will depend on the rapid diffusion of Comprehensive gene sequencing tools. for tissue samples. 

Individually, the mutations are so rare that it is unlikely that the cancer units perform specific tests for each.  

The Roche Medicine Foundation supplies the complete kits, which compete with Thermo Fisher Scientific and Caris Life Sciences. 

"It's one of the reasons we acquired Foundation Medicine, to make this routine routine of genomic profiles and upfront in the course of the disease," said Daniel O'Day, the head of Roche's pharmaceutical division. 

The Loxo larotrectinib pill, developed jointly with Bayer, showed last year that it reduces tumors in 75 percent of patients with NTRK fusion gene abnormality, which occurs in the lung, the pancreas or in more than one Dozen other organs. 

On Sunday, the response rate to larotrectinib within an expanded group of 122 participants in the trial, compared to 55 initially and now encompassing 24 types of tumors, was shown to be 81 percent.     

Roche said that the readings of the two NTRK fusion assays were not comparable because they are composed of different types of patients. The Loxo study, for example, included some types of cancer in children, while Roche plans to investigate them separately. 

The Roche compound is designed to cope with several oncogenic mutations and last month, revealed data here in entrectinib pushing back tumors in 77 percent of patients with lung cancer with a mutation called ROS1. 

Merck & Co's Keytruda in May last year became the first drug to gain approval for the use of tumor tumors, although it remains a relatively small market for the bulk drug. Bayer and Loxo are testing a second pan-tumor drug, LOXO-195.  

O'Day of Roche Pharmaceutical welcomed a wider field. 

"Both must happen: you need a genomic profile and you need enough targeted drugs to encourage doctors to make a very complete diagnosis. This is the world we are entering, "he said. 

While response rates may encourage a breed of more drugs of this type, the need for appropriate mutations or gene fusions will be a difficult task, said oncologist Ulrik Lassen, of the Rigshospitalet in Copenhagen, who is a co-author of the larotrectinib study.  

"It is necessary to examine many patients to find the needle in the haystack and the method is complicated, expensive and time-consuming. When we improve the use of these technologies, we can find more oncogenic mergers and companies will be smart enough to find the agents that attack them. " 

Roche acquired entrectinib as part of its acquisition agreement with the US cancer drug specialist. UU Ignyta Inc. for $ 1,700 million, agreed in December of last year. 

Immunooncology remains another important commercial area for Roche, which also showed positive results when using its drug Tecentriq in a group of patients with breast cancer with a particularly poor prognosis. 





Ludwig Burger report; Edited by Dale Hudson





Our Rules:The principles of trust of Thomson Reuters.

        .

  !function(f,b,e,v,n,t,s)

  {if(f.fbq)return;n=f.fbq=function(){n.callMethod?

  n.callMethod.apply(n,arguments):n.queue.push(arguments)};

  if(!f._fbq)f._fbq=n;n.push=n;n.loaded=!0;n.version='2.0';

  n.queue=[];t=b.createElement(e);t.async=!0;

  t.src=v;s=b.getElementsByTagName(e)[0];

  s.parentNode.insertBefore(t,s)}(window, document,'script',

  'https://connect.facebook.net/en_US/fbevents.js');

  fbq('init', '369524843414444');

  fbq('track', 'PageView');

    .


SOURCE LINK ERESVIRAL.COM 
https://www.beviral.online